Sinusoidal obstruction syndrome
(SOS), formerly known as veno-occlusive disease, is a fatal complication that occurs within the first 35-40 days following myeloablative preparation regimen (e.g., total body irradiation and high dose chemotherapy).
Liver injury may occur with chemotherapy regimens such as irinotecan, which may cause steatohepatitis, and oxaliplatin, which may cause nodular regenerative hyperplasia or sinusoidal obstruction syndrome
(previously known as venoocclusive disease).
Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome
The most likely explanation, besides the fact that the studies were slightly underpowered to detect grades II--IV aGVHD, is that deaths due to post-HCT complications other than GVHD such as excess sinusoidal obstruction syndrome
deaths were accounted for (4).
Hepatic Sinusoidal Obstruction Syndrome
(SOS) and Acute Kidney Injury.
The type of conditioning regimen prior to alloHCT plays a critical role in the development of early hepatic complications occurring as a result of the development of a hepatic venous obstructive disorder (VOD), currently renamed the sinusoidal obstruction syndrome
(SOS) or drug-induced hepatic injury.
Hepatic sinusoidal obstruction syndrome
(SOS), a serious complication that can occur following either allogeneic or autologous hematopoietic stem cell transplantation (HSCT), was described by Tracy Krimmel, MSN, AOCN[R], APRN-BC, and Loretta A.
Because the sinusoidal lesions were similar to those seen in veno-occlusive disease, also termed sinusoidal obstruction syndrome
, the authors gave the name of sinusoidal obstruction syndrome
(SOS) to these vascular lesions.
We did not search for cases of sinusoidal obstruction syndrome
, because of its aforementioned characteristic histologic findings and distinctive clinical setting.
The data showed that defibrotide use in patients with hepatic veno-occlusive (VOD), also called as sinusoidal obstruction syndrome
(SOS), with multi-organ failure (MOF) post-hematopoietic stem-cell transplantation (HSCT) was linked with a statistically essential enhancement in Day +100 survival and in rate of complete response (CR) by Day +100, in comparison with rigorously chosen historical controls.
Individualized therapeutic drug monitoring must be performed to ensure that busulfan concentrations are optimal for treatment and to reduce the risk for graft rejection, disease relapse, and sinusoidal obstruction syndrome
(SOS), previously known as veno-occlusive disease.
Patients with alcoholic hepatitis (23) and sinusoidal obstruction syndrome
(24) occurring in the setting of severe cellular rejection post liver transplant can have similar lesions and can also have noncirrhotic portal hypertension.